CooperVision’s leadership and commitment to transforming the trajectory of myopia in children will be prominently showcased this week at the prestigious 60th International Myopia Conference (IMC) events in Changsha and Sanya, China. Research findings span the company’s comprehensive range of optical interventions, including MiSight® 1 day soft contact lenses and orthokeratology contact lenses.
“Our dedication to advancing the science and practice of myopia management is on full display at IMC, as teams from CooperVision and our research partners around the globe debut significant new studies.”
Elizabeth Lumb, BSc (Hons) MCOptom, FIACLE, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision
In addition, the company is showcasing multiple category experts through its digital platforms throughout the week, including LinkedIn. Researchers and program team members who have been instrumental in developing, sharing, and promoting invaluable myopia control and management science—work that is changing the lives of children worldwide—reflect on their work and its impact. Learn more at https://www.linkedin.com/company/coopervision.
More than a dozen CooperVision authored and supported papers and posters were accepted to this year’s conference. Highlights include:
Myopia Control with MiSight® 1 day Dual Focus Lenses in Chinese Children (Arumugam B, et al). Interim results from an ongoing, double-masked, multi-center randomized clinical trial in China showed considerable efficacy of MiSight® 1 day in slowing myopia progression. Absolute treatment effects for both axial length and cycloplegic refractive error in children enrolled at ages 7 to 11 were even greater than those observed previously in a majority non-Asian cohort (Chamberlain, et al 2019).[1]
Efficacy of OrthoK in Axial Inhibition: A Comprehensive Retrospective Review of Real-World Patient Population from UC Berkeley Myopia Control Clinic (Jung L, et al). The multi-year retrospective review analyzed records of 424 children fit with Paragon CRT® 100 and CRT Dual Axis® between 2008 to 2023, determining that overnight ortho-k effectively slowed myopia progression as measured by axial elongation. The findings add weight to the clinical usefulness of ortho-k treatments and further confirm that younger children have faster axial growth rates than older children. No cases of microbial keratitis were reported, supporting the efficacy and safety of ortho-k in real-word clinical settings.
Assessment of Performance and Satisfaction with Orthokeratology Lens Among Chinese Wearers and their Parents: A Multicenter Study (Zheng Y, et al). Aier Eye Hospital investigators in 10 cities across China enrolled 588 myopic children ages 8-16 who had worn DreamLite® ortho-k contact lensese bilaterally for at least one year, gaining their subjective feedback and those from their parents. Overall, 98% of wearers and 95% of parents expressed outstanding satisfaction, with excellent comfort and sustained ideal levels of unaided vision throughout the day.
Myopic Defocus Introduced by Dual Focus Myopia Control and Orthokeratology Contact Lenses (Walther G, et al). Indiana University and University of California Berkeley researchers sought to characterize the proportions of myopically defocused light delivered to the retina by MiSight® 1 day contact lenses and Paragon CRT Dual Axis® ortho-k lenses (post-treatment) and their effects on image quality. In ten myopic participants ages 22-30, both treatments—despite different optical designs—introduced approximately 50% myopically defocused light and similar image quality to their foveas.
Additional CooperVision-supported papers and posters include an analysis of myopia control prescribing patterns in the U.S., Australia, and New Zealand, extended efficacy data for SightGlass Vision spectacle lenses with Diffusion Optics Technology™*, and research regarding the potential irradiance hazards of red-light therapy.
The company is once again sponsoring the Chew Sek-Jin Memorial Award Lecture on September 26, which will be delivered this year by myopia researcher, author, and tech entrepreneur Professor Ian Flitcroft, DPhil, FRCOphth.
For more details on the 2024 IMC, visit www.internationalmyopiaconference.org.
*This product is not approved in all markets.
[1] 1 Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.
Click HERE for the press release.
Want to see more like this article? Click here to subscribe to our FREE print magazines and e-newsletters!
